Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 1of 32
NON- INTERVENTIONAL (NI) STUDY PROTOCOL
Title Comparative Analy sisof Adherence and 
Effectiveness Outcomes Between 
Rheumatoid Arthritis (RA) Patients Treated 
with Tofacitinib Modified Release (MR) 
Formulation 11mg Once Daily (QD) and
Tofacitinib Immediate Release (IR) 
Formulation 5 mg Twice Daily  (BID) within 
a [LOCATION_002] (US) Healthcare Claims
Database
Protocol number A3921349
Protocol version identifier Version 1
Date 27 March 2019
Active substance L04AA29 (tofacitinib)
Medicinal product Xeljanz (tofacitinib)
Research question and objectives Primary  Objectives:
To compare two proxies of medication
effectiveness (a validated criteria -based 
algorithm and a persistence -based measure) 
over 12 months of follow -up among RA 
patients treated with tofac itinib MR 11 mg 
once dail y and tofacitinib I R 5 mg twice 
daily .
Compare 12- month proportion of RA 
patients who are persistent and adherent with
tofacitinib MR 11 mg once dail y and 
tofacitinib I R 5 mg twice daily .
Secondary  Objectives:
To compare a persiste nce-based measure of 
effectiveness over [ADDRESS_1226496] (IRB)/Independent Ethics Committee (IEC) ..............[ADDRESS_1226497] of the Study ..................................................................................24
10. MANAGEMENT AND REPORTI NG O F ADVERSE EVENTS/ADV ERSE 
REACTI ONS ................................................................
......................................................[ADDRESS_1226498]................................................................
...................................29
ANNEX 4.  CLAIMS -BASED INDEX OF RA SE VERITY (CIRAS) ...................................[ADDRESS_1226499] Biologic disease -modifying antirheumatic drug
BID Twice daily (bis in die)
CIRAS Claims -based index for RA severity
COB Coordination of Benefits
COPD Chronic obstructive pulmonary disease
CPI [INVESTIGATOR_877807] -modifying antirheumatic drug
DAS Disease Activity Sco re
ED Emergency department
ER Emergency room
FDA Food and Drug Administration
GLM Generalized linear model
HCPCS Healthcare Common Procedure Coding System
HIPAA Health Insurance Portability and Accountability Act
ICD-[ADDRESS_1226500] Non-biologic disease- modifying antirheumatic drug
NDC National Drug Code
NIS Non-interventional study
NSAID Non-steroidal anti-inflammatory drug
PDC Proportion of Days Covered
PMDA Pharmaceutical and Medical Devices Agency

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 6of 32Abbreviation Definition
QD Once daily (quaque die)
RA Rheumatoid Arthritis
RCT Randomized controlled trial
RX Outpatient pharmacy prescription
TNFi Tumor -Necrosis Factor -alpha inhibitor
US [LOCATION_002]

Tofacitinib
A3921349 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 7 of 322. RESPONSIBLE PARTIES
Principle Investigator(s) of the Protocol
Name, degree(s) Job Title Affiliation Address
 
, PhD  
,M S  
, PhD  
, PhD   
3. ABSTRACTNot applicable.
4. AMENDMENTS AND UPDATES
None
5. MILESTONES
Milestone Planned date
Start of data collection (programming start) 27 March 2019
End of data collection (draft tables) 16 April 2019 
Interim study report 1 May 2019
Final study report 31 Jan 2020PP
D
[COMPANY_003] [COMPANY_003]
[COMPANY_003] [COMPANY_003]
[COMPANY_003] [COMPANY_003]
[COMPANY_003] [COMPANY_003]
Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 8of 326.RATIONALE AND BACKGR OUND
Tofacitinib 5 mg immediate release formulation (IR) was approved for twice daily  (BID) 
dosing schedule by [CONTACT_2165] (FDA) in November [ADDRESS_1226501] 
had an inadequate response or intolerance to methotrexate. In Febru ary 2016, an 11 mg once 
a day  (QD) modified release (MR ) tablet for treatment of rheumatoid arthritis was approved 
in the [LOCATION_002].  It may  be used as monotherapy  or in combination with methotrexate
(MTX) or other conventional sy nthetic disease -modify ing antirheumatic drugs 
(csDMARDs ). 
Biologic disease -modify ing antirheumatic drugs s (bDMARDs) have been 
used for man y years to treat RA with vary ing levels of success; however, no study  has 
compared the effectiveness and treatment patterns of tofacitinib to bDMARDs in a real -world
setting.
In stud y A3921215, a randomised controlled direct comparative clinical study conducted in 
Japan , the MR formulation did not meet the non- inferiorit y criteria based on the stringent 
criteria requested b y the Pharmaceutic al and Medical Devices Agency  (PMDA ), the 
Regulatory  Agency in Japan. However, the point estimate of the difference in efficacy  
between the MR and IR formulations, based on the primary  endpoint of Disease Activity  
Score ( DAS )28, was within the pre -specifi ed margin. Nonetheless, the data from this study  
are not sufficient to c onclude statistical similarity
 between the clinical efficacy  of MR and IR 
formulations. While randomised controlled trials (RCT) are considered high in the hierarch y 
of medical evide nce for a conventional treatment compari son, the A3921215 results may not 
be applicable to clinical practice due to many  factors including reduced adherence. Patients 
tend to demonstrate worse adherence when they  know their medication is being monitored. 
For example, i n a metanaly sis of RCTs that used electronic pi[INVESTIGATOR_877808], patients had 
lower adherence in studies where they  were blinded to the fact of monitoring than in studies 
where they  were aware of the monitoring .[ADDRESS_1226502] masked the benefit of the MR 11 mg QDformulation relative to 
IR 5 mg BID by [CONTACT_877819] y arms . 
Increasingl y, there is a recognition that 
patientsâ€™ use of medicines in regular clinical practice 
or in settings better reflecting the reality  of he althcare delivery can explain differences 
between expected efficacy  based on RCT outcomes and actual effectiveness in real world.1  
Evidence from medication use in the real-world setting can help to extrapolate an d/or 
augment data obtained in randomised controlled trials and establishes a broad pi[INVESTIGATOR_510] a 
medicationâ€™s place in every day clinical practice .[ADDRESS_1226503] initiation, tofacitinib MR 11 mg QD is effective in 
managing signs and s ymptoms of RA in real world clinical use; and that it does so to a 
similar degree as tofacitinib I R 5mgBID formulation ([COMPANY_007], data on fil e).  However, 
adherence information is not collected in the register and could not be evaluated.

Tofacitinib
A3921349 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 9 of 32This study is designed to compare the RA patient adherence betwe en patients initiating 
tofacitinib MR 11 mg QD to those starting IR 5 mg BID, and to co mpare two proxy measures 
of effectiveness in an insurance claims-based real-world data set ting.  
7. RESEARCH QUESTION AND OBJECTIVES
Primary Objectives:
To compare, through multivariate regression analyses:
â€¢Two proxies of medication effectiveness (a validated criteria-ba sed algorithm and a 
persistence-based measure)3over 12 months of follow-up among RA patients treated 
with tofacitinib MR 11 mg once daily and tofacitinib IR 5 mg twi ce daily.
â€¢12-month proportion of RA patients who are persistent and adhere nt with tofacitinib
MR 11 mg once daily and tofacitinib IR 5 mg twice daily.
Secondary Objectives:
To compare, through multivariate regression analyses:
â€¢A persistence-based measure of effectiveness over 6 months of fol low-up among RA 
patients treated with tofacitinib MR 11 mg once daily and tofacitin ib IR 5 mg twice 
daily.
â€¢A 6-month proportion of RA patients who are persistent and adher ent with tofacitinib
MR 11 mg once daily and tofacitinib IR 5 mg twice daily.
 
 
8. RESEARCH METHODS 
8.1. Study Design
To address the objectives, a retrospective cohort design will be e mployed to evaluate patient
characteristics, proportion persistent and adherent, and effectiv eness proxies in RA patients 
newly initiating tofacitinib within the Truven Health MarketScan Re search Databases,
 
8.2. Setting
This study will utilize the de-identified claims data in the Tru ven Health MarketScan
Research Databases.CCI
CC
I
Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 10of 328.2.1. Inclusion Criteria
This study will include individuals with RA who are commercially  insured (commercial 
claims and encounters database) or Medicare -eligible retirees with employ er sponsored 
Medicare Supplemental coverage (Medicare database) who are treated with tofacitinib .
Patients must meet all of the following inclusio n criteria to be eligible for inclusion in the 
study :
1.First pharmacy  claim for tofacitinib isa 30-day supply (index event).
2.Index prescription isfor labelled dosing for tofacitinib MR 11 mg QD or IR 5 mg 
BID between 01 March 2016 and 31 October 2018 (theidentification period) (See 
Annex 2 for operationalization) .Since the specific dose frequency , ie, twice daily  or 
once dail y is not available, forthose initiating a [ADDRESS_1226504] y of tofacitinib MR 11 
mg, a quantity  of 30 pi [INVESTIGATOR_877809] ( ie, 1x11 mg per day ) and for those starting a 
30days suppl y of tofacitinib 5 mg, 60 pi[INVESTIGATOR_3353] (2x5 mg per day ) will be required. 
Patients from the overall cohort will be further assigned into MR [ADDRESS_1226505] 1year after the index date.
Note: Patients will have a variable length baseline of at lea st a year long. The
baseline period will be censored at January  1,
[ADDRESS_1226506] measures will use data during the entire 
variable length baseline.
4.Presence of The International Classification of Diseases, 9thRevision or 10th
Revision, Clinical Modification (I CD-9 CM or ICD -10 CM) code for RA (in any
position) during the one -yearpre-index period or on the index date .  
ICD-9 = 714.0x -714.4x & 714.81 or ICD10 = M05.* & M06.0*- M06.3* or 
M06.8*
-M06.9*.
5.At least [ADDRESS_1226507] one claim for methotrexate anytime pre -index .
8.2.2. Exclusion Criteria
Patient s meeting any of the following criteria willnot be included in any study cohort :
1.Patients with claims for other conditions for which advanced therapi[INVESTIGATOR_014] (bDMARD or 
Janus Kinase inhibitor (JAK) ) are used during the one -year pre-index period or on the 
index date: anky losing spondy litis, Crohnâ€™s diseas e, psoriasis, psoriatic arthritis,
juvenile idiopathic arthritis or ulcerative colitis will be excluded from the study .

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 11of 32Table 1. Exclusionary Diagnosis
Disease ICD-9 diagnosis code ICD10 diagnosis code
Ankylosing Spondylitis 720.0x M45.*
Crohn's Disease 555.xx K50.*
Psoriasis 696.1x L40.0* -L40.4*, L40.8* -L40.9*
Psoriatic Arthritis 696.0x L40.5*
Ulcerative Colitis 556.xx K51.*
Juvenile RA 714.3* M08.*
ICD: International classification of diseases; RA = rheumatoid arthritis
2.Patients with evidence of the index medication during the one -year pre-index period .  
Patients will be allowed to have been treated with other advanced therapi[INVESTIGATOR_877810] s or other JAK inhibitor s(not tofacitinib) during the one -year 
pre-index period.
3. Patients with more than one advanced therapy prescription fill on the index date will 
be removed from the study , ie, a bDMARD and JAK inhibitor or more than one JAK 
inhibitor or two different tofacitinib formulations (ie, IR and MR) , filled on the index 
date will be removed from the study .
8.3.Cohort Assignment
Patients will be assigned to a tofacitinib study cohort based on the firsttofacitinib claim and 
formulation observed and for which the patient meets the other inclusion/exclusion criteria
While patients may  have multiple eligible treatment epi[INVESTIGATOR_1841], only 
the first will be evaluated . 
Patients whose first tofacitinib prescription reflects a [ADDRESS_1226508] 
24 months ([ADDRESS_1226509] index, at minimum) .  Patients will 
have a variable length pre-index baseline period of at least [ADDRESS_1226510] RA diagnosis, the entire variable length baseline period will be utilized. The 
twelve months following the index date willbe used to assess outcomes including adherence, 
persistence, and medication effectiveness.
8.5.Variables
Adherence is defined as percentage of time with medication on hand and will be assessed 
with t he M edication Possession R atio (MPR) and Proportion of Days Covered (PDC) .  Both 
measures have been eval uated in numerous publications for rheumatoid arthritis and other 
conditions andwill be reported in current study for 6 and 12-month follow -up periods.   Both 

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 12of 32adherence measures willleverage tofacitinib medication day s supply  in the numerator, for 
which PDC adjusts for overlap in prescriptions while MPR does not . Further, the PDC is a 
more conservation measure of adherence as the denominator includes al l pre-defined 
follow -up (360 day s for the 12-month period; 180 day s for the 6-month period ),which may  
include time after stoppi[INVESTIGATOR_007] a medication in the calculation, while MPR only  includes time 
between firstandlastprescription (plus last prescription day s supply )in the denominator .  
Patients with an MPR or PDC â‰¥0.[ADDRESS_1226511] 1/3rdof  patients are not persistent with TNFi therap y, which is 
consistent with proportion of patients with inadequate response in clinical trials.[ADDRESS_1226512] not discontinued 
(gap of 60 day s between 
refills) or switched medications; however, it may  underestimate theproportion who are 
persistent depending on the duration of gap(ie, 60 vs. 90 day s) for patients tha t may  appear to 
discontinue and resume treatment for multiple reasons including hospi[INVESTIGATOR_059], drug samples
not recorded in claims ,use of stockpi[INVESTIGATOR_5829], etc. Hence sensitivity  analy ses with different gaps 
are often employ ed. 
Two measures of effectiveness will be used in this study : 1) a validated algorithm -based, 
dichotomous measure (over the 12 month follow up period) and 2) a duration of therap y 
based co ntinuous measure of medication persistence (over 6 and 12 month follow up 
periods) . 
Among patients with at least one yearof follow up, medication effectiveness at one y ear after
the index date will be determined using an algorithm
-based prox y measure of effectiveness 
based on the following six criteria.3,[ADDRESS_1226513] good sensitivity , 
specificit y, positive and negative predictive values ranging from 75% to 90% using a gold 
standard of low disease activity  (DAS28 â‰¤3.2) or improvement in DAS28 by  >1.[ADDRESS_1226514] Rheumatoid Arthritis (EULAR) responder definition.[ADDRESS_1226515] of the following: the date of last 
prescription that is followed b y a gap of 60 days without evidence of another advanced 
therap y prior to expi[INVESTIGATOR_877811]; the day  before receipt of another advanced therapy ; or the 
end of follow up period.  

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 13of 32Table 2. Variab les U sed in Analyses
Variable Role Operational definition
Index date Baseline Patient 
CharacteristicsMonth and year of the patientâ€™s treatment index date 
(seeSection 8.2.1 , 8.2.2 ).
Age Baseline Patient 
CharacteristicsPatient age as of the index date .
Age group Baseline Patient 
CharacteristicsAge categorized into: 18 â€“44, 45â€“ 64, and 65+.
Sex Baseline Patient 
CharacteristicsMale or female. 
Geographic region Basel ine Patient 
CharacteristicsRegion in which the study patient is enrolled in a 
health plan will be categorized into five geographic 
regions: Northeast, North Central, South, West, and 
Unknown .
Insurance type Baseline Patient 
CharacteristicsInsurance type (commercial or Medicare )of index 
claim .
bDMARD use, [ADDRESS_1226516] one 
prescription (Annex 2 ) received during the [ADDRESS_1226517] one 
prescription ( Annex 2 ) received during the entire 
variable length pre -index period. No use will be 
classified as bDMARD naÃ¯ve. Use of 1, [ADDRESS_1226518] one 
prescription ( Annex 2 ) received durin g the 12 month 
pre-inde x period .Will characterize use of 0, 1, 2 or 
more TNFiâ€™s.
TNFi  use, [ADDRESS_1226519] one 
prescription ( Annex 2 ) received during the entire 
variable length pre -index period. No use will be 
classified as TNFi naÃ¯ve. Use of 1, 2 or more will be 
classified as TNFI experienced.

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 14of 32Table 2. Variab les U sed in Analyses
Variable Role Operational definition
Advanced therapy use 12 
month pre -index, 
categoricalBaseline Clinical 
CharacteristicsUse of bDMARDs or JAK inhibitors ( Annex 2 ) 
during 12 months pre -index.  Will characterize use 
of 0,1, 2or more advanced t herapi[INVESTIGATOR_014] .
Advanced therapy use 12 
month pre -index, 
continuousBaseline Clinical 
CharacteristicsNumber of unique medications and claims during 
12months pre -index.  
Advanced therapy use, 
variable length pre -index, 
categoricalBaseline Clinical 
CharacteristicsUse of any bDMARDs or JAK inhibitors ( Annex 2 ) 
during variable length pre -index period. No use will 
be classified as advanced therapy naÃ¯ve. Use of 1, [ADDRESS_1226520] one 
prescription (see Annex 2 ) during the [ADDRESS_1226521] medications and
claims (see Annex 2 ) during 12-month pre -
index 
period .
csDMARD use, [ADDRESS_1226522] -index (including 
index)Baseline Clinical 
CharacteristicsCombination therapy defined as first comedication 
with any csDMARD ( Annex 2 ) within [ADDRESS_1226523] classify as >1 csDMAR Dother 
than methotrexate.
Monotherapy defined as the complement to 
combination therapy.
Quan -Charlson comorbidity 
score, continuous ,12-
month pre -indexBaseline Clinical 
CharacteristicsA weighted scale of 17 co -morbidities (based on 
associated diagnosis codes on medical claims in the 
12-months pre -index) presented as a summative 
score to evaluate co-morbid chronic illness burden
.
Quan -Charlson comorbidity 
score, categorical 12-month 
pre-indexBaseline Clinical 
CharacteristicsThe continuous Quan -Charl son comorbidity score 
categorized into:  0, 1 -2, 3-4, 5+ QCCI comorbidities
(Annex 3 ).4,9
Opi[INVESTIGATOR_2480], non -steroidal anti -
inflammatory drug 
(NSAI D) use, dichotomous, 
12-month pre -index Baseline Clinical 
CharacteristicsThe use of weak and/or strong opi[INVESTIGATOR_50942]/or non -
steroidal anti -inflammatory drug (NSAID) 
(
Annex 2) during the 12 -month pre -index periods.
Opi[INVESTIGATOR_2480], non -steroidal anti -
inflammatory drug 
(NSAID) use, continuous 
12 month pre -indexBaseline Clinical 
CharacteristicsThe number of pharmacy claims for weak and/or 
strong opi[INVESTIGATOR_50942]/or non -steroidal 
anti-inflammatory drug (NSAID) (Anne x 2) during 
the 12 -
month pre -index periods.

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 15of 32Table 2. Variab les U sed in Analyses
Variable Role Operational definition
Pre-index corticosteroids, 
dichotomousBaseline Clinical 
CharacteristicsThe use of oral corticosteroids (Annex 2) during the 
12-month pre -index .
Pre-index corticosteroid 
total exp osure/dose, 
continuous, 12 -month pre -
indexBaseline Clinical 
CharacteristicsThe total prednisone -equivalent dose of oral 
corticosteroids in the 12 months prior to index, 
defined as: the  sum of prednisone equivalent dose 
(Strength* quantity/ equivalence fac tor) of a filled 
corticosteroid . (Dose equivalent factors: 
Betamethasone=0.6, Dexamethasone=0.75; 
Methylprednisolone, Triamcinolone=4, Prednisone, 
Prednisolone=5; Hydrocortisone=20, Cortisone=25; 
Fludrocortisone=n/a) .
Visit with a rheumatologist 
in [ADDRESS_1226524] one ambulatory visits (office visit or 
outpatient visit) in which the physician was a 
rheumatologist in the [ADDRESS_1226525] one ambulatory visits (office visit or 
outpatient visit) in which the physician was a 
rheumatologist in the [ADDRESS_1226526] 
in12 months prior to index, 
continuous Baseline Clinical 
CharacteristicsCount of Ambulatory visits (office visit or outpatient 
visit) in which the physician was a rheumatologist in 
the [ADDRESS_1226527] claim with a 
diagnosis of RA in the variable length baseline until 
the index date.
Total all-cause costs, 12-
month pre -index, 
continuousBaseline Clinical 
CharacteristicsSum of patient and plan p aid costs for all healthcare 
resource use in 12 month pre -index period.  CPI 
[INVESTIGATOR_877812] 2018 dollars (http://data.bls.gov/cgi -
bin/surveymost?cu U.S. Medical Care, 1982 -
84=100 - CUUR0000SAM) . 
Comorbidities, 12 month 
pre-index, dichotomous
Cardiovascular diseases
Chronic obstructive 
pulmonary disease (COPD)
Asthma
Kidney disease
Diabetes
Depression
Anxiety
Liver disease
Sleep disorders
Hypertension
Hyperlipi[INVESTIGATOR_877813] 12 -months prior to index
(Annex 2).

Tofacitinib
A3921349 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 16 of 32Table 2. Variables Used in Analyses
Variable Role Operational definition
Pre-index Claims-based 
index for RA severity 
(CIRAS), 12 month pre-
index, continuousBaseline clinical 
characteristicThe Claims-based Index for RA Severity will be 
implemented. CIRAS provides a single value of 
severity using the following 9 measures: age, 
gender, inflammatory marker tests, rehabilitation 
visits, Felty Syndrome, platelet orders, rheumatoid 
factor tests, chemistry panels, and rheumatologist 
visits.  Scores range from 0 (low) to 
10 (high)( Annex 4 ).10
Length of variable length 
pre-index period, 
continuousBaseline characteristic The period from start of continuous enro llment 
through index without gaps in coverage.  
Length of variable length 
pre-index period, 
categoricalBaseline characteristic Continuous variable length duration cate gorized into 
<13, 13-18, 19-24, 25-30,31-36 and >[ADDRESS_1226528]-index, 
dichotomous Outcome (persistence) Patients who do not have a switch to anoth er 
advanced therapy or discontinue tofacitinib (ie, 
60-day gap between the run out of prior tofacitinib 
prescription and subsequent fill) over 6 and 
12 month follow-up periods are characterized as 
persistent.  The run out date is the prescription fill 
date + day supply â€“ 1.  For retail outpatient 
pharmacy prescription (RX) claims, the day supply 
will be utilized.  There are no null tofacitinib days 
supply in dataset; however, claims with negative 
days supply or zero days supply will be excluded.  
Most tofacitinib prescriptions are for 30 days supply 
(86%) followed by 90 (12%) and 60 (~1%) days. 
Patients with early refills will be allowed to 
accumulate a stockpi[INVESTIGATOR_877814] 14 days for later use. 
A change in the formulation of active ingredient 
prescribed, eg, 5 mg BID vs 11 mg QD is not 
considered a switch for persistence endpoints in 
primary analyses.
Medication Possession Ratio (MPR), [ADDRESS_1226529]-index, 
continuousOutcome (adherence) The total days supply between the first and including 
the last tofacitinib prescription divided by [CONTACT_877820]. Multiple 
prescriptions for the same treatment with the same 
fill date will be treated as one prescription with 
longest days supply; and for all prescriptions days 
supply will be capped at end of follow-up. MPR 
will be capped at 1.0 and will be reported at 
6 months and 12 months.
Medication Possession 
Ratio (MPR), [ADDRESS_1226530]-index, 
dichotomous  Outcome (adherence) High adherence (MPRâ‰¥0.8) vs. Low Adherence 
(MPR <0.8).
Proportion of Days Covered 
(PDC), [ADDRESS_1226531]-index, continuousOutcome (adherence) The PDC was defined as number of days covere d by 
[CONTACT_877821] [ADDRESS_1226532]-index. 
Patients with early refills will be allowed to stockpi[INVESTIGATOR_877815] a maximum of 14 days total for 
later use. PDC is capped at 1.0.
Proportion of Days Covered 
(PDC), [ADDRESS_1226533]-index, dichotomousOutcome (adherence) High adherence (PDCâ‰¥0.8) vs. Low Adherence ( PDC 
<0.8).CCI
Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, [ADDRESS_1226534] -index, 
dichotomousOutcome (effectiveness) Patients who meet all 6 effectiveness criteria will be 
considered effectively treated. Patients who fail any 
one of the 6 criteria are considered not effectively 
treated.
High adherence criterion Effectiveness criterion 1 High adherence criterion met if PDC >=0.8 during 
the 12 month follow -up period.
Dose escalation criterion Effectiveness criterion 2 No dose esc alation criterion is met if no increases in 
index medication dose between index and 12 months 
after index. Dose increase threshold defined per 
Table 3.
No treatment switch 
criterionEffectiveness criterion 3 No tre atment switch criterion is met if there is no use 
of an advanced therapy ( Annex 2) other than index 
therapy during the [ADDRESS_1226535]-index for which there was not a claim during 
1-year pre -index and/or [ADDRESS_1226536]-index .
Oral glucocorticoids 
criterionEffectiveness criterion 5 The oral glucocorticoids criterion is met if  a) For 
patients with no oral glucocorticoid prescriptions in 
the [ADDRESS_1226537] index; b) For patients 
with at least one claim for or al glucocorticoids 
during [ADDRESS_1226538] -index 
compared to the 6 months before the index date. 
Dose increase is defined as â‰¥20% increase in 
prednisone equivalent dose (per above) for all 
glucocorticoid claims filled during the respective 
time periods.
Note:  Patients with more than one glucocorticoid 
injection during months [ADDRESS_1226539] failed the criterion. 
Medication effectiveness, 
Duration of therapy 
(persistence), continuous, 
[ADDRESS_1226540] -index Outcome (effectiveness 
proxy)The number of days between index dat e to the first 
of the following: the date of last prescription that is 
followed by a gap of 60 days without evidence of 
another advanced therapy prior to expi[INVESTIGATOR_877811]; 
the day before receipt of another advanced therapy; 
or the end of follow up period.
A sensitivity analysis will be conducted for the 
Tofacitinib MR and IR comparison to include a 
switch in formulation as a criterion for 
discontinuation.

Tofacitinib
A3921349 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, [ADDRESS_1226541] dosing schedule Criteria for dose escalatio n for medication
effectiveness
Tofacitinib
(tofacitinib IR)[ADDRESS_1226542] 20 mg/day.
tofacitinib(tofacitinib MR)[ADDRESS_1226543] 22 mg/day.
 
 
 
 
 
 
 
 
 CCI
Tofacitinib
A3921349 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 20 of 32 
 
 
 
 
 
 
 
 
 
 C
CI
Tofacitinib
A3921349 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 21 of 32 
 
 
 
 
8.7. Study Size
The sample size for this study is fixed by [CONTACT_877822]. No formal sample size computation  was performed.  All 
patients who meet inclusion/exclusion criteria will be included  in the analyses.
8.8. Data Management 
The MarketScan Research Databases comply with both the spi[INVESTIGATOR_877816] d the letter of the Health 
Insurance Portability and Accountability Act of 1996 (HIPAA).  Th e MarketScan Databases
meet the criteria for a limited-use dataset and contain none of t he data elements prohibited by
[CONTACT_410011]-use datasets.
8.9. Data Analysis 
8.9.1. Primary and Secondary Analyses 
Descriptive and multivariate regression analyses will be perform ed to satisfy the primary and 
secondary analyses as described in Table 4.  Details on the desc riptive and multivariate 
methods follow in Section 8.9.[ADDRESS_1226544] Index 
DurationAnalysisa
Effectivenessb
(algorithm defined)Primary Dichotomous 12 months Generalized 
linear model
Effectivenessc
(duration of persistence)Primary Continuous 12 months Cox regression
Adherence 
(MPR)Primary Continuous 12 months Generalized 
linear model
Adherence 
(MPR â‰¥80%) Primary Dichotomous 12 months Logistic 
regression
Adherence (PDC)Primary Continuous 12 months Generalized 
linear model
Adherence (PDC â‰¥80%)Primary Dichotomous 12 months Logistic 
regression
Effectiveness 
(duration of persistence)Secondary Continuous 6 months Cox regression
Adherence 
(MPR)Secondary Continuous 6 months Generalized 
linear model
Adherence (MPR â‰¥80%) Secondary Dichotomous [ADDRESS_1226545] Index 
DurationAnalysisa
Adherence 
(PDC)Secondary Continuous 6 months Generalized 
linear model
Adherence (PDC â‰¥80%)Secondary Dichotomous 6 months Logistic 
regression
a. Analyses will be repeated stratifying by [CONTACT_877823] a dvanced treatments (0, 1, and 2+ prior) if 
feasible.b. The proportions of patients not meeting each of the [ADDRESS_1226546]-index 
measures will be provided, and appropriate tests (eg, t-test, M ann Whitney-U test, chi-square 
test) will be used based on the distribution of the measure. The  analysis that is performed (ie, 
the methods that are used and the patients who are included) wi ll be specific the objective 
being examined.  Descriptive techniques will be implemented for  each objective. 
8.9.3. Multivariate Analysis
To control for possible confounding of the relationship between  the outcomes and 
independent variable of interest multivariable (logistic, gener alized linear, and Cox) 
regression models will be evaluated as described in Table 4 . 
The models will include insurance type, region, age, sex, prior advance therapi[INVESTIGATOR_877817] (None, 1 and 2+) as covariates.  The following va riables will be evaluated for 
inclusion as a covariate and be included if differences between  MR 11 mg QD and IR 5 mg 
BID at baseline with p <0.10: 12-month pre-index use (% and mea ns) of csDMARD, opi[INVESTIGATOR_2438], 
corticosteroids and presence of comorbidities including, cardio vascular disease, chronic 
obstructive pulmonary disease (COPD), asthma, kidney disease, d epression, anxiety, liver 
disease, sleep disorders, hypertension, hyperlipi[INVESTIGATOR_035], Quan-Ch arlson comorbidity index and 
CIRAS scores, rheumatologist visit count during 1-year pre-inde x, disease duration, 
pre-index total costs, length of pre-index period, use of advan ced therapy in [ADDRESS_1226547]-index.  
Generalized linear models (GLM) will be fit, using appropriate distributions and links for the 
nature of the data (eg, normally-distributed data with identity  link, binary data and logit link).  
Point estimates, 95 percent confidence intervals, and p-values will be presented for contrasts; 
analysis of variance table will be presented to display the stre ngth of the independent CCI
Tofacitinib
A3921349 NON-INTERVENTIONAL STUDY PROTOCOL
Version 1, [ADDRESS_1226548] or tofacitinib in
the baseline can be considered to be prior users of therapy; however, pati ents with no
bDMARD or tofacitinib use in the baseline may have just been off therapy for the [ADDRESS_1226549] and tofacitinib users. Effectiveness (yes/no) wil l be measured using a 
validated algorithm; however, the algorithm was not validated for all medications being
included. Specifically, tofacitinib was approved for treatment of RA after the algorithm was
developed. This study will include consultation with physicians to determine if the algorithm 
is valid for all study medications or if modifications need to be  implemented.CCI
Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, [ADDRESS_1226550] to the processing of 
personal data, when study  data are compi[INVESTIGATOR_168024], an y patie nt names will be removed and will be replaced by  a single, specific, 
numerical code .  All other identifiable data transferred to [COMPANY_007] or other authorized parties 
will be identified by  [CONTACT_20007], patient -specific code .  In case of data transfer, [COMPANY_007] will 
maintain high standards of confidentialit y and protection of patientsâ€™ personal data consistent 
with the vendor contract and applicable privacy  laws.
9.2.Patient 
Consent
As this study  does not involve data subject to privacy  laws according to applicable l egal 
requirements ,obtaining informed consent from patie nts by  [CONTACT_16099]. 
9.3.Institutional Review Board (IRB)/Independent Ethics C ommittee 
(IEC)
IRB is not required forthis study as it uses commercially available de- identified secondary
data sources and is considered exempt from the requirements for â€œhuman subjects researchâ€
in the US.
9.4.Ethical Conduct of the Study
The study  will be conducted in accordance with legal and regulatory  requirements, as well as 
with scientific purpose, value and rigor and follow generall y accepted research practices 
described in CT24 -WI-GL02 -RF04 and the International Society forPharmacoeconomics 
and Outcomes Research (I SPOR).
10.MANAGEMENT AND REPOR TING OF ADVERSE EVEN TS/ADVERSE 
REACTIONS 
This study  involves data that exist as structured data by  [CONTACT_410013] a 
combination of existing structured data and unstructured data, which will be converted to 
structured form during the implementation of the protocol solely  by a computer using 
automated/algorithmic me thods, such as natural language processing.

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 25of 32In these data sources, individual patient data are not retrieved or validated, and it is not 
possible to link (ie, identify  a potential association between) a particular product and medical 
event for an y individu al.  Thus, the minimum criteria for reporting an adverse event (AE) (ie, 
identifiable patient, identifiable reporter, a suspect product, and event) cannot be met.
11.PLANS FOR DISSEMINAT ING AND COMMUNICATING STUDY RESULTS
For all publications relating to the Study ,[COMPANY_007] will comply with recognized ethical
standards concerning publications and authorship, including Section II -â€œEthical
Considerations in the Conduct and Reporting of Researchâ€ of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by [CONTACT_4717].
In the event of an y prohibition or restriction imposed (eg, clinical hold) by [CONTACT_220009] y in any area of the world, or if the part y responsible for collecting data 
from the participant is aware of an y new information which might influence the evaluation of 
the benefits and risks of a [COMPANY_007] product , [COMPANY_007] s hould be informed immediately .

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 26of 3212.REFERENCES
1. Association of British Pharmaceutical Industry  (ABPI) Securing a Future for Innovative 
Medicines: a discussion paper. 2014 Available at: 
http://www.abpi.org.uk/media/1432/securingafuture_final.pdf   Accessed 23 March 
2019.
2. Coleman CI, Limone B, Sobieraj DM, Lee S, Robe rts MS, Kaur R, Alam T. Dosing 
frequency  and medication adherence in chronic disease. J Manag Care  
Pharm. 2012 Sep;18(7):527 -39.
3. Curtis JR, Baddley  JW, Yang S, et al. Derivation and preliminary  validation of an 
administrative claims -
based algorithm for the effectiveness of medications for 
rheumatoid arthritis. Arthritis Res Ther 2011 ;13(5):R155.
4. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity  index for use with 
ICD-9-CM administrative databases. J Clin Epi[INVESTIGATOR_5541]. 1992;45:613 â€“ 619.
5. Harne tt J, Wiederkehr D, Gerber R, et al.  Real- world evaluation of TNF -inhibitor 
utilization in rheumatoid arthritis, J Med Econ 2016;2(19):101
-12.
6. Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity  to supplement 
existing evidence for the use of long-established medicines in health care decision 
making. J Multidiscip Healthc 2018;2(11):295 -304. 
7. Oladapo, et. al. Medication Effectiveness with the Use of Tumor Necrosis Factor 
Inhibitors Among [LOCATION_007] Medicaid Patients Diagnosed with Rheumatoid Arthri tis.
J Manag Care Pharm 2014;7(20): 657-67.
8. Pharmacy  Quality Alliance (PQA), Adherence 2018.  Available at: 
https://www.pqaalliance.org/adherence -measures, Accessed 23 March 2019.
9. Quan H , Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders L D, Beck 
CA, Feasb y TE, Ghali WA. Coding algorithms for defining comorbidities in I CD-9-
CM and I CD-10 administrative data. Med Care. 2005 Nov;43(11):1130 -
9.
10. Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation 
data-based index for rheumatoid arthritis severity : a preliminary  study .  Arthritis Res 
Ther. 2008;10(4):R95. 
11. Wolfe, F. The epi[INVESTIGATOR_877818]
, Baillieres 
Clin Rheumatol 1995;9:619-632.

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, [ADDRESS_1226551] will be maintain ed in the study folder.  QCCI is a weighted sum of 
0/1indicator variables for 17 disease categories.  The weights are: 
1*(cci01+cci02+cci03+cci04+cci05+ cci06+cci07+cci08+cci09+cci10)
2*(cci11+cci12+cci13+cci14)
3*(cci15)
6*(cci16+cci17) 
cci01 = 'Myocardial infarction (MI)'
cci02 = 'Congestive heart failure (CHF)'
cci03 = 'Peripheral vascular disease 
(PVD)'
cci04 = 'Cerebrovascular disease 
(CD)'
cci05 = 'Dementia'
cci06 = 'Chronic pulmonary disease 
(CPD) '
cci07 = 'Rheumatologic disease (RD)'
cci08 = 'Peptic ulcer disease (PUD)'
cci09 = 'Mild liver disease (MLD)'
cci10 = 'Diabetes without chronic 
complication'
cci11 = 'Diabetes with chronic 
complications'
cci12 = 'Hemiplegia or paraplegia'
cci13 = 'Renal disease'

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 30of 32cci14 = 'Any malignancy, including 
leukemia and lymphoma'
cci15 = 'Moderate or severe liver disease'
cci16 = 'Metastatic solid tumor'
cci17 = 'AIDS/HIV'

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 31of 32ANNEX 4.  CLAIMS -BASED INDEX OF RA SE VERITY (CIRAS)
Measure10Score
Age(continuous) -0.066
Gender
0:male
1:female-0.092
Inflammatory marker testordered
0:no
1:yes0.60
Rehabilitation visit
0:no
1:yes0.[ADDRESS_1226552]
0:no
1:yes2.1
Feltyâ€™s syndrome
0:no
1:yes2.3
Number ofplatelet counts ordered
0 = 0 visits
1 = 1 visit
2 = 2 visits
3 = 3 visits
4 =4+visits0.42
Number ofchemistry panels ordered
0 = 0 panels
1 = 1 panel
2 = 2 panels
3 = 3 panels
4 = 4 panels
5 =5+panels-0.[ADDRESS_1226553] visit count
1 = 0 visits
2 = 1-4 visits
3 =5+visits0.[ADDRESS_1226554] visits are counted 1 per person per day.

Tofacitinib
A3921349 NON -INTERVENTIONAL STUDY PROTOCOL
Version 1, 27 March 2019
Page 32of 32Codes for CIRAS Calculation 
Codes Visits/Tests 
Inflammatory 
Markers85651, [ZIP_CODE] 
[ZIP_CODE], 86141ESR
CRP
Rehabilitation OT/PT Codes: G0151,G0152,G0157,G0158, 
G0159,G0160,S9129,S9131,[ZIP_CODE],[ZIP_CODE],970
03,97004Occupational therapy/physical 
therap y visits
Rheumatoid 
FactorCPT [ZIP_CODE],[ADDRESS_1226555] Quant
Feltyâ€™s 
syndromeICD- 9/10: 714.1, M05.0x
Platelet counts CPT: [ZIP_CODE] Automated platelet count
Chemistry 
panelsCPT: [ZIP_CODE], [ZIP_CODE], [ZIP_CODE], [ZIP_CODE], [ZIP_CODE],
[ZIP_CODE], [ZIP_CODE], [ZIP_CODE], 84550A/G Ratio, Albumin, Alkaline 
Phosphatase, Alanine 
Aminotransferase, Asparate 
Aminotransferase, Direct and 
Total Bilirubin, 
BUN/Creatinine Ratio, 
Calcium, Carbon Dioxide, 
Chloride, Cholesterol, 
Creatinine, Gamma 
Glutamyltransferase, Globulin, 
Glucose, Iron, Lactate 
Dehydrogenase, Phosphate, 
Potassium, Total Protein, 
Sodium, Triglycerides, Urea 
Nitrogen (BUN), Uric Acid

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	

	
'RFXPHQW 7LWOH	

	
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
 		!"" 
#  $
 		"	"!
 
  $ 		"" 
#  $	 	"	"! 
  $[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]